Ritter Daniher Financial Advisory LLC DE Acquires Shares of 4,267 IQVIA Holdings Inc. $IQV

Ritter Daniher Financial Advisory LLC DE bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,267 shares of the medical research company’s stock, valued at approximately $810,000.

Several other institutional investors also recently bought and sold shares of IQV. Versant Capital Management Inc grew its position in shares of IQVIA by 6.3% during the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after buying an additional 53 shares in the last quarter. Private Trust Co. NA lifted its stake in IQVIA by 12.5% in the second quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares during the period. CVA Family Office LLC lifted its position in shares of IQVIA by 11.6% in the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after purchasing an additional 68 shares during the period. E Fund Management Co. Ltd. increased its holdings in IQVIA by 3.7% during the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock valued at $331,000 after buying an additional 74 shares during the period. Finally, Harbor Capital Advisors Inc. increased its holdings in shares of IQVIA by 2.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 2,795 shares of the medical research company’s stock valued at $531,000 after acquiring an additional 78 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IQV. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Stifel Nicolaus increased their price target on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Barclays set a $230.00 price target on IQVIA in a research note on Monday, December 15th. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. Finally, Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $251.06.

IQVIA Price Performance

NYSE:IQV opened at $235.26 on Friday. The firm has a market cap of $40.06 billion, a price-to-earnings ratio of 32.27, a PEG ratio of 2.43 and a beta of 1.36. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The firm’s fifty day moving average is $230.84 and its two-hundred day moving average is $207.70.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.84 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.